Primary prevention of atherosclerotic vascular disease with ethylnandrol. An interim report of four-year observations.
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000517:prevention & control*; D001219:Aspartate Aminotransferases / Q000097:blood; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D005032:Ethylestrenol / Q000009:adverse effects / Q000627:therapeutic use*; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000453:epidemiology; D007564:Japan; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D010919:Placebos; D012712:Serum Globulins; D012995:Solubility; D014280:Triglycerides / Q000097:blood
D010919:Placebos; D012712:Serum Globulins; D014280:Triglycerides; D005340:Fibrinogen; D002784:Cholesterol; D005032:Ethylestrenol; D001219:Aspartate Aminotransferases